![](https://endpts.com/wp-content/uploads/2017/07/pascal-soriot-endpts-endpoints-APimages.jpg)
AstraZeneca's prized Imfinzi/tremelimumab combo fails again — this time in head and neck cancer
AstraZeneca’s big bet on a combination of its checkpoint inhibitor Imfinzi and in-house CTLA-4 drug has proved exceedingly costly. The British drugmaker conceded on Friday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.